Abstract
Abstract:Ketobemidone is a mu receptor agonist, available in Scandinavia in a combined preparation (Ketogan$$), which contains ketobemidone and the spasmolytical agent 3‐dimethylamino‐1, 1‐diphenylbutene (A29) in a one to five ratio. A29 is chemically related to methadone and experiments in rats have shown that A29 potentiates the analgesic effect of ketobemidone (Petersen 1951). We have recently shown that ketobemidone has lower binding affinity for the total mu receptor than morphine. At $$‐binding sites the two opioids have equal affinity, whereas ketobemidone has much lower affinity than morphine to the $$ receptor (Christensen 1993). The existence of two subtypes of mu receptors has been suggested by Pasternak and co‐workers: a high affinity, mu1receptor subtype that appears to mediate supraspinal analgesia and a low affinity, mu2subtype that appears to mediate spinal analgesia, respiratory depression and inhibition of gastrointestinal motility (Clarket al.1988; Paulet al.1989).
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call